1) To receive, process, and store blood samples in an efficient and organized manner from CLL patients that have been diagnosed at various sites across the country. The first step will involve collecting, processing, labeling, and storing the sample received from each patient. The second step will be the distribution of the sample to various sites for addition studies as requested by the investigators of the CRC. In addition, the Tissue Core will assure accurate quality control, record keeping, and data management. Approximately 2,000 samples will be collected per year. 2) To provide a central repository for CLL blood samples with basic minimum information. When the samples are received by the Tissue Core, they will be assigned a unique patient identifier number and logged into a database. This database will be updated as information is received on the subsequent samples that are collected from the CLL patients. 3) To make the viably frozen samples readily available to the CRC investigators for future research studies. The investigators of the CRC will be able to request frozen vials needed for event-driven studies (hypothesis testing) by submitting a sample request a sample request form. This form requires a description of the proposed hypothesis, the outcome of the project, the biostatistician appraisal, the number & type of samples required, and the approval of the advisory committee. 4) To perform basic panel of tests. The basic tests that will be conducted on each patient sample as it is newly diagnosed will be: A- immunophenotyping analysis (Flow cytometry) to assess extent of disease and B- (AN-PCR-ELISA) to determine expressed Ig VH subgroup. Cytogenetic Minimal Residual Disease (MRD), and Los of Heterozygosity (LOH) testing will be performed on specific CLL samples only according to hypothesis-driven studies. These studies will be outlined in the sample request forms that will be received by the Tissue Core director and evaluated.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Barr, Paul M; Robak, Tadeusz; Owen, Carolyn et al. (2018) Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 103:1502-1510
Kondo, K; Shaim, H; Thompson, P A et al. (2018) Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia 32:960-970
Hasan, Md Kamrul; Yu, Jian; Widhopf 2nd, George F et al. (2018) Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood 132:170-178
Ten Hacken, Elisa; Valentin, Rebecca; Regis, Fara Faye D et al. (2018) Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight 3:
Gribben, John G (2018) How and when I do allogeneic transplant in CLL. Blood 132:31-39
Sivina, Mariela; Werner, Lillian; Rassenti, Laura et al. (2018) Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol 180:597-600
Ott, Christopher J; Federation, Alexander J; Schwartz, Logan S et al. (2018) Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell 34:982-995.e7
Balatti, Veronica; Tomasello, Luisa; Rassenti, Laura Z et al. (2018) miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood 132:2179-2182
Vangapandu, Hima V; Chen, Huiqin; Wierda, William G et al. (2018) Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma 59:1427-1438
Yu, Jian; Chen, Yun; Chen, Liguang et al. (2018) Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget 9:24731-24736

Showing the most recent 10 out of 562 publications